
|Articles|July 1, 2003
Expanding Possibilities
San Francisco - The expanding indications for the topical immune response modulator imiquimod (Aldara) may soon include treatment of superficial basal cell carcinoma (BCC), Mark Naylor, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














